Data From Multiple Clinical Trials Of OrbusNeich's Genous(TM) Bio-engineered R Stent(TM) To Be Presented At TCT 2008

Main Category: Cardiovascular / Cardiology
Also Included In: Clinical Trials / Drug Trials;  Conferences
Article Date: 07 Oct 2008 - 0:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2008, in Washington, D.C.

Robbert de Winter, M.D., Ph.D., of the Academic Medical Center in Amsterdam will provide a Genous clinical program update in an oral presentation at 4:10 p.m. EDT on Oct. 13 in Ballroom C at the Washington Convention Center. His presentation will include interim follow-up data from e-HEALING, a monitored, multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients.

In addition, de Winter and his colleagues will provide one-year follow-up data in an electronic poster that will be available for download and viewing throughout the convention center. Titled "One-year Clinical Outcome of a Real World Experience in Patients Treated with a Genous EPC Capturing Stent," the poster will reflect the use of the Genous stent in 236 patients who were considered to be mainly high risk in the study conducted exclusively at the Academic Medical Center.

Also scheduled for presentation in an electronic poster are one-, six- and 12-month follow-up data from studies involving acute myocardial infarction (AMI) patients at National University Hospital (NUH) in Singapore. The poster titled "The Impact of Endothelial Progenitor Cell Capture Stent Implantation in Patients with Acute Myocardial Infarction: Intermediate to Long Term Clinical Follow-Up" summarizes the studies conducted by Huay-Cheem Tan, M.D., and collaborators.

An additional electronic poster that demonstrates the clinical efficacy and safety of Genous versus a sirolimus-eluting stent and a bare metal stent in patients with ST-segment elevation myocardial infarction (STEMI) at NUH will be presented by Eric Chong, M.D. and collaborators. The poster is titled "Comparison of 24-Month Clinical Outcome of Endothelial Progenitor Cell Capture Stent versus Sirolimus-Eluting Bioabsorbable Polymer-Coated Stent versus Bare Metal Stents in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

In another oral presentation at TCT 2008, Robert Cottone, OrbusNeich's vice president of intellectual property and technologies, will describe the design concept for the company's bioabsorbable stent and its development program. Cottone's presentation will take place at 5:04 p.m. EDT on Oct. 13 in Ballroom C at the convention center.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Scoreflex(TM), Sapphire(TM), Sapphire(TM) NC, Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

OrbusNeich
http://www.OrbusNeich.com